Chemours Company (NYSE: CC) closed the day trading at $26.10 down -0.08% from the previous closing price of $26.12. In other words, the price has decreased by -$0.02 from its previous closing price. On the day, 1146010 shares were traded.
Ratios:
For a better understanding of CC, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.08 and its Current Ratio is at 1.68. In the meantime, Its Debt-to-Equity ratio is 5.60 whereas as Long-Term Debt/Eq ratio is at 5.50.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, UBS on March 05, 2024, Downgraded its rating to Neutral and sets its target price to $21 from $37 previously.
On February 29, 2024, BMO Capital Markets Downgraded its rating to Underperform which previously was Outperform and also lowered its target price recommendation from $45 to $19.
RBC Capital Mkts Upgraded its Sector Perform to Outperform on December 01, 2023, whereas the target price for the stock was revised from $28 to $40.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jun 09 ’23 when Newman Mark bought 7,661 shares for $34.63 per share. The transaction valued at 265,300 led to the insider holds 266,955 shares of the business.
Scarborough Alvenia sold 5,125 shares of CC for $165,537 on Jun 09 ’23. The SVP Corp Communications & CBO now owns 13,890 shares after completing the transaction at $32.30 per share. On Jun 08 ’23, another insider, Abbott Matthew S, who serves as the SVP, Chief Enterprise Transfor of the company, sold 8,912 shares for $34.20 each. As a result, the insider received 304,790 and left with 29,869 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CC now has a Market Capitalization of 3.87B and an Enterprise Value of 7.25B. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.65 while its Price-to-Book (P/B) ratio in mrq is 5.13. Its current Enterprise Value per Revenue stands at 1.21 whereas that against EBITDA is 38.99.
Stock Price History:
Over the past 52 weeks, CC has reached a high of $39.05, while it has fallen to a 52-week low of $15.10. The 50-Day Moving Average of the stock is 28.81, while the 200-Day Moving Average is calculated to be 30.49.
Shares Statistics:
Over the past 3-months, CC traded about 1.88M shares per day on average, while over the past 10 days, CC traded about 5.44M shares per day. A total of 148.50M shares are outstanding, with a floating share count of 146.69M. Insiders hold about 1.18% of the company’s shares, while institutions hold 76.70% stake in the company. Shares short for CC as of Feb 29, 2024 were 4.71M with a Short Ratio of 2.50, compared to 4.93M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 3.17% and a Short% of Float of 4.25%.
Dividends & Splits
CC’s forward annual dividend rate is 1.00, up from 1.00 a year ago. Against a Trailing Annual Dividend Yield of 3.83%, it implies a Forward Annual Dividend Yield of 3.83%. The stock’s 5-year Average Dividend Yield is 4.21.
Earnings Estimates
Current recommendations for the stock of the company come from 9 analysts. On average, analysts expect EPS of $0.25 for the current quarter, with a high estimate of $0.43 and a low estimate of $0.12, while EPS last year was $0. The consensus estimate for the next quarter is $0.85, with high estimates of $1 and low estimates of $0.7.
Analysts are recommending an EPS of between $3.46 and $2.85 for the fiscal current year, implying an average EPS of $3.02. EPS for the following year is $3.72, with 10 analysts recommending between $4.28 and $3.05.
Revenue Estimates
5 analysts predict $1.32B in revenue for the current quarter. It ranges from a high estimate of $1.36B to a low estimate of $1.22B. As of the current estimate, Chemours Company’s year-ago sales were $1.34B, an estimated decrease of -1.60% from the year-ago figure. For the next quarter, 4 analysts are estimating revenue of $1.55B, an increase of 5.90% over than the figure of -$1.60% in the same quarter last year. There is a high estimate of $1.62B for the next quarter, whereas the lowest estimate is $1.46B.
A total of 8 analysts have provided revenue estimates for CC’s current fiscal year. The highest revenue estimate was $6.04B, while the lowest revenue estimate was $5.88B, resulting in an average revenue estimate of $6B. In the same quarter a year ago, actual revenue was $6.79B, down -11.70% from the average estimate. Based on 8 analysts’ estimates, the company’s revenue will be $6.22B in the next fiscal year. The high estimate is $6.5B and the low estimate is $5.91B. The average revenue growth estimate for next year is up 3.70% from the average revenue estimate for this year.
